Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advanced Non-Small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Immunotherapy.

Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Jan 2000

Nie Wei, Xu Mi-Die, Gan Lu, Zhang Yi, Qian Jie, Gu Kai, Zhang Xue-Yan, Wang Hui-Min, Yan Bo, Gu Ping, Zhang Bo, Wang Shu-Yuan, Hu Fang, Li Chang-Hui, Zhong Hua, Han Bao-Hui

Abstract excerpt

The aim of this study is to investigate the association between tumor mutation burden (TMB) and survival in non-small cell lung cancer (NSCLC) patients with anti-programmed cell death protein 1 and anti-programmed death-ligand 1 blockade. Two retrospective cohorts and The Cancer Genome Atlas NSCLC data set were included in this study. The restricted cubic spline analysis was used to explore the association...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to DNA Damage

Share to Neoplasm Staging

Share to Programmed Cell Death 1 Receptor

Share to T-Lymphocytes

Source

Identifiers

PMID: 32209830
DOI: 10.1097/CJI.0000000000000318

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advanced Non-Small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Immunotherapy.PMID 32209830Read ↗

The landscape of tumor mutational burden and its clinical significance in patients with lung cancer: a Multi-omics study with a meta-analysisSemantic proximity Read ↗

Prognostic value of tumor mutation burden in non-small cell lung cancer: A Meta-Analysis and system reviewSemantic proximity Read ↗

UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer.Semantic proximity Read ↗

Integrating Histologic and Genomic Characteristics to Predict Tumor Mutation Burden of Early-Stage Non-Small-Cell Lung CancerSemantic proximity Read ↗

Genomic and TCR Repertoire Intratumor Heterogeneity of Small-cell Lung Cancer and its Impact on SurvivalSemantic proximity Read ↗

Clinical and technical insights of tumour mutational burden in non-small cell lung cancer.Semantic proximity Read ↗

Genomic and TCR Repertoire Intratumor Heterogeneity of Small-cell Lung Cancer and its Impact on SurvivalSemantic proximity Read ↗

A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab.Semantic proximity Read ↗

Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report.Semantic proximity Read ↗

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer.Semantic proximity Read ↗

Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.